Pds Biotechnology Corp PDSB
We take great care to ensure that the data presented and summarized in this overview for PDS Biotechnology Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PDSB
View all-
Vanguard Group Inc Valley Forge, PA1.52MShares$2.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$813,2340.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$693,2380.0% of portfolio
-
Inspirion Wealth Advisors, LLC344KShares$575,1370.18% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$391,1290.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA134KShares$224,2140.0% of portfolio
-
Blair William & CO Chicago, IL122KShares$203,3100.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il115KShares$192,0190.0% of portfolio
-
State Street Corp Boston, MA112KShares$186,7610.0% of portfolio
-
Northern Trust Corp Chicago, IL92.8KShares$154,9640.0% of portfolio
Latest Institutional Activity in PDSB
Top Purchases
Top Sells
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Insider Transactions at PDSB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 02
2022
|
Frank Bedu Addo President/CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
175,184
-20.23%
|
$1,576,656
$9.78 P/Share
|
Dec 02
2022
|
Frank Bedu Addo President/CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
219,535
+20.22%
|
$1,317,210
$6.57 P/Share
|
Dec 13
2021
|
Matthew C Hill Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
200
+2.42%
|
$1,800
$9.0 P/Share
|
Dec 13
2021
|
Matthew C Hill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,900
+25.6%
|
$23,200
$8.95 P/Share
|
Jun 16
2021
|
De Lyle W Bloomquist |
BUY
Open market or private purchase
|
Direct |
10,000
+4.9%
|
$90,000
$9.88 P/Share
|
Jun 16
2021
|
De Lyle W Bloomquist |
BUY
Exercise of conversion of derivative security
|
Direct |
2,970
+1.59%
|
$14,850
$5.99 P/Share
|
Jun 15
2021
|
Gregory Gene Freitag |
BUY
Open market or private purchase
|
Direct |
5,882
+11.3%
|
$47,056
$8.5 P/Share
|
Jun 15
2021
|
Seth Van Voorhees Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
17,647
+50.0%
|
$141,176
$8.5 P/Share
|
Jun 15
2021
|
Kamil Ali Jackson |
BUY
Open market or private purchase
|
Direct |
11,764
+50.0%
|
$94,112
$8.5 P/Share
|
Jun 15
2021
|
Steve C Glover |
BUY
Open market or private purchase
|
Direct |
5,882
+8.44%
|
$47,056
$8.5 P/Share
|
Jun 15
2021
|
Frank Bedu Addo President/CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
27,166
-4.03%
|
$325,992
$12.86 P/Share
|
Jun 15
2021
|
Frank Bedu Addo President/CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,174
+7.32%
|
$319,044
$6.57 P/Share
|